Undisclosed ARV7/NONO modulator / Talus Bio - LARVOL DELTA

Targeting NONO as a therapeutic strategy for metastatic castration-resistant prostate cancer (mCRPC) (AACR 2026) - "Several advanced analogs exhibit improved solubility, enhanced microsomal stability, and overall favorable ADME/PK profiles. Based on these results, we are advancing our most promising candidates into proof-of-concept in vivo efficacy studies to evaluate their potential as first-in-class NONO/AR-targeting therapeutics for mCRPC."

Metastases • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Targeting NONO as a therapeutic strategy for metastatic castration-resistant prostate cancer (CRPC) (AACR 2025) - "While these findings are promising, the application of NONO inhibition as a treatment for mCRPC is still under investigation. Further studies are necessary to confirm its efficacy and safety in clinical settings."

Metastases • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor